Sanara MedTech (NASDAQ:SMTI) Upgraded by Wall Street Zen to Buy Rating

Wall Street Zen upgraded shares of Sanara MedTech (NASDAQ:SMTI) from a hold rating to a buy rating in a research note released on Saturday.

Several other equities analysts have also recently weighed in on the stock. Zacks Research cut shares of Sanara MedTech from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of Sanara MedTech in a report on Thursday, January 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $36.00 price objective on shares of Sanara MedTech in a research note on Monday, January 26th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $36.00.

Sanara MedTech Stock Down 5.8%

Sanara MedTech stock opened at $16.96 on Friday. Sanara MedTech has a 1-year low of $16.05 and a 1-year high of $35.95. The firm has a market capitalization of $155.52 million, a price-to-earnings ratio of -4.01 and a beta of 1.04. The firm’s fifty day moving average price is $19.99 and its two-hundred day moving average price is $24.37. The company has a current ratio of 1.80, a quick ratio of 1.60 and a debt-to-equity ratio of 7.75.

Sanara MedTech (NASDAQ:SMTI) last issued its quarterly earnings data on Tuesday, March 24th. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.07). The business had revenue of $27.55 million for the quarter, compared to analyst estimates of $27.90 million. Sanara MedTech had a negative net margin of 36.42% and a negative return on equity of 20.73%. On average, equities research analysts predict that Sanara MedTech will post -1.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sanara MedTech

Several institutional investors have recently bought and sold shares of the company. Rhumbline Advisers grew its holdings in Sanara MedTech by 14.9% during the first quarter. Rhumbline Advisers now owns 3,714 shares of the company’s stock valued at $115,000 after purchasing an additional 483 shares during the period. Hsbc Holdings PLC bought a new stake in shares of Sanara MedTech in the second quarter valued at $382,000. Marshall Wace LLP lifted its position in shares of Sanara MedTech by 144.3% during the 2nd quarter. Marshall Wace LLP now owns 71,511 shares of the company’s stock valued at $2,030,000 after buying an additional 42,237 shares during the last quarter. Lazard Asset Management LLC lifted its position in shares of Sanara MedTech by 63,100.0% during the 2nd quarter. Lazard Asset Management LLC now owns 3,160 shares of the company’s stock valued at $89,000 after buying an additional 3,155 shares during the last quarter. Finally, Stonebridge Wealth Management LLC bought a new position in shares of Sanara MedTech during the 2nd quarter worth $3,397,000. Hedge funds and other institutional investors own 8.10% of the company’s stock.

Sanara MedTech Company Profile

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.